Lupin Limited (LUPIN) announced the appointment of Brian Savage as President, Chief Legal Officer. Brian will lead Lupin’s global Legal, Compliance, and Intellectual Property Management Group (IPMG) functions and will be based in New Jersey. Brian joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015. Most recently, he served as Teva’s Executive Vice President and Interim Global Chief Legal Officer. During his tenure, he also led Teva’s global litigation strategy and served as General Counsel for its U.S. Generics business.

Extensive Legal Expertise

Brian brings extensive experience navigating the complex legal and regulatory landscape in the global pharmaceutical industry. He holds a Juris Doctor (J.D.) from Yale Law School and a B.A., summa cum laude, from the University of Pennsylvania. Commenting on the appointment, Lupin CEO Vinita Gupta and Managing Director Nilesh Gupta said, “We are delighted to welcome Brian to our executive leadership team. His deep understanding of the pharmaceutical industry landscape, extensive legal expertise, and proven leadership will be valuable as we continue to strengthen our governance framework, navigate an evolving regulatory environment, and advance our long term growth ambitions.”

Leadership Role

In his new role, Brian will oversee all legal, compliance, and intellectual property functions across Lupin’s global operations. His appointment is expected to further enhance the company’s governance and regulatory compliance framework, ensuring alignment with global best practices and industry standards.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Lupin Limited

Lupin Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Lupin drops 19.7% over three months and trades near its 52-week lows. The PEG of 0.12 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.1% and profits at 131.5% CAGR. That is strong double-digit growth on both counts. The stock sits at 10% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. The business compounds at 19.1% revenue and 131.5% profit CAGR, with D/E of 0.32. Yet the stock drops 19.7% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Lupin Limited.

CORONA Remedies Limited (CORONA) has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its Bhayla manufacturing facility in Ahmedabad. This certification covers both Oral Solid Dosage (OSD) and Women’s Hormone production lines. This milestone further strengthens CORONA’s manufacturing credentials and reaffirms its commitment to maintaining high standards of quality, compliance, and operational excellence.

Reaffirming the Philosophy of ‘One World, One Quality’

While India will remain the company’s primary market, contributing over 96% of its revenue, the ANVISA GMP certification further strengthens CORONA’s manufacturing credentials. This marks CORONA’s third major GMP accreditation, building on its EU-GMP approvals for the Women’s Hormone and OSD facilities and its EAEU-GMP certification for the OSD facility. Brazil represents one of the largest pharmaceutical markets in Latin America, with an estimated market size of USD 44 billion, presenting opportunities for pharmaceutical manufacturers with strong quality systems and regulatory capabilities.

Commitment to Quality and Compliance

Together, these recognitions reflect the company’s continued focus on strengthening quality systems, maintaining regulatory compliance, and fostering a culture of continuous improvement across its manufacturing operations. Commenting on this achievement, Mr. Viral Sitwala, Executive Director, CORONA Remedies Limited, said: “Quality has always been central to the way we work at CORONA Remedies. Our philosophy of ‘One World, One Quality’ reflects our belief that the standards we follow must remain consistent and uncompromised. The ANVISA GMP certification for our Bhayla manufacturing facility is an important recognition of the systems, discipline, and collective efforts that go into maintaining these standards. While India remains our primary market and the focus of our business, such accreditations further strengthen our manufacturing credentials and reaffirm our commitment to quality and compliance. We will continue to strengthen our capabilities and uphold the quality standards that guide everything we do.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 2.07 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.14. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.07 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.

Sagility Limited (NSE: SAGILITY) has announced its Q2 FY27 results, showcasing robust performance with 11.9% year-over-year constant currency organic growth. The company won $40.2M in ACV from 31 existing clients and 1 new logo, indicating increasing traction in larger deals.

Financial Highlights

The financial performance highlights include a revenue of ₹ 20,321 Million, an Adjusted EBITDA of ₹ 5,353 Million, and an Adjusted PAT of ₹ 3,254 Million. The company’s margin stood at 26.3% for Adjusted EBITDA and 16.0% for Adjusted PAT.

Growth and Expansion

Sagility’s growth is further supported by its acquisition of Chirok Health LLC, which adds specialized CDI and coding capabilities, extending its end-to-end RCM offering and unlocking new growth opportunities. The acquisition is expected to broaden Sagility’s provider footprint and deliver greater client value.

As a result, Sagility continues to strengthen its market position and drive forward-looking growth prospects.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of SAGILITY LIMITED

SAGILITY LIMITED belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

SAGILITY rises 8.5% over three months, with buying pressure holding steady. The PEG of 0.25 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.5% and profits at 86.1% CAGR. That is strong double-digit growth on both counts. The stock holds at 43% of its 52-week range with RSI at 56. In other words, neither side has a clear edge right now. Revenue grows at 19.5% and profits at 86.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of SAGILITY LIMITED.